The National Institutes of Health (NIH) is a critical pillar of the U.S. public health system and a beacon of guidance for healthcare best practices across the globe. This has never been more evident than during the COVID-19 crisis. A lesser-known NIH facet is its long and productive history of technology transfer success.
This year, Maryland continued to prove why it’s becoming one of the strongest biohealth clusters in the country. The state’s commitment to businesses in the life science, pharmaceutical, and biotech industries has continued as both the private and public sectors work to meet the demand for more space. Here are a few of the biggest real estate projects in Maryland in 2021. Some of these projects are still under construction, while others were unveiled this year.
Dr. Kayla Valdes is a Senior Manager at Horizon Therapeutics, a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare diseases. Prior to joining Horizon, Dr. Valdes worked at the National Institutes of Health as a Senior Program Manager on the Cure Sickle Cell Initiative. She was also the Associate Director of Scientific Programs at the Drug Information Association (DIA), where she developed DIA’s global content strategy by providing scientific expertise in therapeutic drug development and regulatory policy.
BioHealth Capital Region Retains Strong Grip on No. 4 Spot of Top 10 U.S. Biopharma Hubs Eyes Third Spot by 2023
As a life sciences cluster, the BioHealth Capital Region is poised to become a top-three cluster in the Genetic Engineering & Biotechnology News (GEN) Top 10 Biopharma Clusters ranking on the strengths of early-stage companies becoming commercial successes and the construction of millions of square feet of new wet lab space.
BioHealth Innovation Adds Diane Ignar, Ph.D. and Dr. Loleta Robinson as NIH New Entrepreneurs-in-Residence
BioHealth Innovation Inc. (BHI) announces the addition of Diane Ignar, Ph.D., and Dr. Loleta Robinson to the expanding Entrepreneurs-in-Residence (EIR) team. The Entrepreneur-in-Residence Program at BHI ensures that disruptive technologies receive all the resources required to transform the technology from a discovery into a commercially relevant product and eventually have a measurable impact on human health. The program was created to support scientists, early-stage startups, and licensed technologies to provide them with access to these resources. Diane will work with NIH’s National Institute on Aging, and Loleta will work with their Office of Extramural Research.
5 Questions with Stephanie M. Davis, Ph.D., Program Officer, National Heart, Lung, and Blood Institute
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region and beyond to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome Stephanie M. Davis, Ph.D., Program Officer, National Heart, Lung, and Blood Institute. Stay tuned for more interviews with others from across the BioHealth Capital Region and beyond.
Rockville’s Integrated BioTherapeutics Inc. Awarded $16.3M Contract from the National Institute of Allergy and Infectious Diseases to Develop a Treatment for Marburg Virus Disease
Integrated BioTherapeutics Inc. (IBT), a Maryland biotechnology company specializing in emerging infectious diseases, announced today the receipt of a contract valued at up to $16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal antibody for treatment of Marburg virus disease (MVD). MVD is caused by either of two marburgviruses, Marburg virus and Ravn virus, and has reemerged several times since it was initially described in 1967. IBT-T03H, discovered in collaboration with the University of Maryland, has been shown in preclinical studies to be protective against both Marburg and Ravn virus.
The Tumor-Infiltrating Lymphocytes (TIL) Cell Processing Modular Facility is the first large-scale, fully prefabricated and modular multi-module cGMP manufacturing facility of its kind ever built in the United States. The National Cancer Institute (NCI) will utilize the facility to deliver cutting-edge cancer treatment.
Leading coronavirus scientist, Kizzmekia S. Corbett, to join Harvard T.H. Chan School of Public Health to continue vaccine development research
Leading coronavirus scientist Kizzmekia S. Corbett is joining Harvard Chan School as an assistant professor to continue vaccine development research.
The National Institutes of Health provides significant funding for drug development research to universities, companies, and organizations. Over the course of 2020, the NIH provided a significant amount of funding to the BioHealth Capital Region.